<DOC>
	<DOCNO>NCT01565291</DOCNO>
	<brief_summary>A preliminary study test florbetapir F 18 ( 18F-AV-45 ) act brains body healthy elderly people patient Alzheimer 's Disease ( AD ) use positron emission tomography ( PET ) scanner .</brief_summary>
	<brief_title>A Preliminary Study 18F-AV-45 Alzheimer 's Disease Healthy Elderly Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Inclusion Criteria ( AD group ) : Probable AD accord National Institute Neurological Communication Disorders StrokeAlzheimer 's Disease Related Disorders Association ( NINCDSADRDA ) criteria Mild/moderate dementia evidence mini mental state exam ( MMSE ) score range 10 24 , boundary include , screen History cognitive decline gradual onset progressive period least 6 month Inclusion Criteria ( healthy volunteer group ) : No evidence significant cognitive impairment history psychometric test MMSE 29 high Exclusion Criteria ( group ) : Neurodegenerative disorder AD Cognitive impairment result trauma , hypoxic damage , vitamin deficiency , brain infection , brain cancer , endocrine disease , mental retardation Clinically significant infarct possible multiinfarct dementia define NINCDS criterion Evidence screen MRI biomarker suggest alternate etiology cognitive deficit ( healthy control , evidence suggest presence AD pathology ) Clinically significant psychiatric disease History epilepsy convulsion Clinically significant hepatic , renal , pulmonary , metabolic , endocrine disturbance Current clinically significant cardiovascular disease Received investigational medication within last 30 day</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Amyloid imaging</keyword>
	<keyword>Positron Emission Tomography</keyword>
	<keyword>18F-AV-45</keyword>
	<keyword>florbetapir F 18</keyword>
	<keyword>Diagnostic imaging</keyword>
</DOC>